Order Growth from Exclusive Worldwide Distribution of Deltagen’s Knockout Mice
First written in FY2016. 1 of 2 entries say "Restated". Latest entry: FY2017.
No other company in this theme has enough history to compare yet.
- FY2017RestatedAnnual report
「We will also focus on strengthening orders by leveraging the exclusive worldwide sales rights entered into with US-based デルタジェン社, which produces and holds approximately 900 strains of knockout mice, centred on genes with high potential as drug-discovery targets, including G-protein-coupled receptors (GPCRs).」
The Company has reaffirmed its policy of using デルタジェン社's approximately 900 strains of knockout mice and exclusive worldwide sales rights to strengthen orders. - FY2016First statedAnnual report
「We will also focus on strengthening orders by leveraging the exclusive worldwide sales rights entered into with US-based デルタジェン社, which produces and holds approximately 900 strains of knockout mice, centred on genes with high potential as drug-discovery targets, including G-protein-coupled receptors (GPCRs).」
The Company will use its exclusive worldwide sales rights with US-based デルタジェン社, which holds approximately 900 strains of knockout mice, to strengthen orders.